Tag:
sepsis
Latest Headlines
Latest Headlines
Sirius Genomics preps for sepsis research
There is only one approved treatment for sepsis on the market: activated protein C. But due to potential side effects, activated protein C isn't universally prescribed. Sirius Genomics hopes to help
Lilly spins off sepsis drug into a biotech start-up
Eli Lilly has inked a deal with a pair of investors--Care Capital and NovaQuest Capital--to spin off a sepsis drug into a new biotech in Indiana dubbed BioCritica which plans to build a pipeline of
Eisai scraps blockbuster app after Ph3 sepsis drug trial derails
Just two months ahead of its self-imposed deadline to file a marketing app for a sepsis drug with blockbuster potential, Japan's Eisai says that it is now scrapping those plans after the therapy
ALSO NOTED: CRO market hits $14B; Merck ends BioXell pact; and much more...
> Merck has ended its collaboration with BioXell on its sepsis drug TREM-1. BioXell says it will seek another company with which to partner on the drug. Report > Shire
Press Release: AlphaRx Inc. Provides Positive Update On Indaflex
Press Release: AlphaRx Inc. Provides Positive Update On Indaflex
New trial for CytoFab as investors urge action
AstraZeneca is planning a new mid-stage trial of CytoFab for severe sepsis which will take 21 months to complete. The prospect of a delay for CytoFab hammered the share price of the UK's Protherics, which licensed the drug to AstraZeneca 11 months ago in a deal valued at up to $372 million. The move could delay AstraZeneca's plans to launch a Phase III trial in 2007, which would delay a potential market launch. But company officials cautioned that a successful new mid-stage trial could …
ALSO NOTED: Ariad selling shares; Indevus gains milestone; Barr closing on Pliva; and much more...
> Ariad Pharmaceuticals is selling 3.1 million shares in a public offering. Report
> Indevus Pharmaceuticals has received a $10 million milestone payment from Esprit Pharma, the company's partner in the U.S. for Sanctura and and Sanctura XR. …
NIH group accuses Lilly of manipulating guidelines
A group of top scientists at the NIH have accused Eli Lilly of orchestrating the creation of medical guidelines in order to push sales of its sepsis drug Xigris. And they add that the company is now lobbying to make the use of Xigris for sepsis a quality standard that would earn physicians who use the drug additional bonus funds. Senior NIH investigator Dr. Peter Q. Eichacker says that people deserve to see medical …
Start-up pockets $39M, licenses new biologic
Artisan Pharma has raised $39 million in its first round of financing. NGN Capital led the round in a syndicate with JAFCO, New Leaf Venture Partners, Bio*One Capital and NovaQuest. As part of the financing, Asahi Kasei Pharma Corporation has licensed a late-stage clinical development biologic, ART-123, to Artisan. The experimental biologic is being studied as a therapy for disseminated intravascular coagulation in sepsis and deep vein thrombosis. The license includes development and …
ALSO NOTED: XTL raises $28M; Wex to cut jobs; hedge fund resists Chiron acquisition;and much more...
> Israel's XTL Biopharmaceuticals has raised $28 million from a private placement. Report
> Canada's Wex Pharmaceuticals is handing out pink slips to about half of its 100 workers as it moves to shave about a million dollars in annual expenses. Earlier this month Wex announced unfavorable interim results for a study of …
